Method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -132.53% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTXenetic Biosciences, Inc.'s latest supported as-filed period reports revenue of $660,601, 12.0% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -132.53% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 11.99% · CORE
Level · gp.fundamentals.operating_margin
Raw value -147.09% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 83.56% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 7.87% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +35.4% from the comparable as-filed period.
Net income changed -35.0% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Operating income changed -34.1% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
XBIO · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001683168-26-006077SEC ↗10-QAug 6, 2026Period Jun 30, 20260001683168-26-006061SEC ↗8-KMay 13, 2026Period May 13, 20260001683168-26-003766SEC ↗10-QMay 12, 2026Period Mar 31, 20260001683168-26-003727SEC ↗10-K/AApr 24, 2026Period Dec 31, 20250001683168-26-003207SEC ↗8-KApr 24, 2026Period Apr 21, 20260001683168-26-003203SEC ↗4Apr 23, 2026Period Apr 21, 20260001683168-26-003163SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Apr 21, 2026Filed Apr 23, 2026 | PARSLOW JAMES FInterim CEO and CFO | Grant Or AwardDirect | 100,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating margin changed -2429 basis points from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Research & development changed -15.9% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Revenue changed +12.0% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Stock-based compensation changed +231.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001683168-26-001744